BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Diopsys Inc.: New Software for Improving the Analysis of OCT Images


12/20/2010 11:56:43 AM

PINE BROOK, N.J., Dec. 20, 2010 /PRNewswire/ -- Diopsys, Inc. today announced the development of software that uses existing Spectral Domain Optical Coherence Tomography (SD-OCT) images to assist ophthalmologists and optometrists in diagnosing retinal and optic nerve disease such as glaucoma.

SD-OCT is an imaging technique used to provide ophthalmologists and optometrists thickness measurements of the Retinal Nerve Fiber Layer (RNFL) which can help them diagnose diseases like glaucoma. However, this thickness can be unduly influenced by retinal vessels and other factors within the RNFL.

The new software (Diopsys® CORDA) works by analyzing the internal structure of the RNFL through discrimination of its different components. As a result, ophthalmologists and optometrists get a more accurate reading of the RNFL health from their OCT images, and can more precisely diagnose and track diseases. This software will also help detect vision disorders earlier so that patients can begin treatment sooner.

According to literature, current thickness algorithms in OCT technology may overestimate sectors with focal defects in the RNFL causing this layer to look more substantial. Using the new software, ophthalmologists and optometrists will be able to hone in on just the structure that is damaged by glaucoma. "The Diopsys® CORDA software was developed not only for diagnosing glaucoma and its progression, but also for the evaluation of other ophthalmic conditions like ischemic and inflammatory optic neuropathies," says Alberto Gonzalez Garcia, M.D., neuro-ophthalmologist and Research Director at Diopsys, Inc.

Because Diopsys® CORDA works with all existing SD-OCT images including those from Carl Zeiss, Meditec, Heidelberg Engineering, Optovue and Topcon devices, the accuracy and clinical value of these OCT machines are improved without having to purchase new hardware.

About Diopsys

Diopsys, Inc. (http://www.diopsys.com) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care. The company specializes in the development and marketing of patient-friendly, non-invasive diagnostic vision testing equipment. Diopsys has developed and markets the patented Enfant® Pediatric Vision Testing System, a device used by pediatricians in testing for visual deficits, including amblyopia, in children as young as six months of age. Diopsys also developed and markets the Diopsys® NOVA-DT (Diagnostic & Tracking), Diopsys® NOVA-TR (Transient Response) and Diopsys® NOVA-DN (Diseases of the Optic Nerve) Vision Testing Systems utilized by ophthalmologists and optometrists for the detection, diagnosis and treatment of vision disorders.

SOURCE Diopsys, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES